As per enclosed letter.

Divi 's Laboratories Limited August 01, 2026 To To The Secretary The Secretary National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Trading Symbol: DIVISLAB Scrip Code: 532488 Dear Sir / Madam, Sub: Outcome of Board Meeting held on August 01, 2026 Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Further to our letter dated July 20, 2026, we would like to inform that the Board of Directors of the Company at its meeting held on August 01, 2026, has approved, inter alia, the following items of business: Financial Results Approved the unaudited financial results for the quarter ended June 30, 2026. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of unaudited standalone financial results for the quarter ended June 30, 2026 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of unaudited consolidated financial results for the quarter ended June 30, 2026, and Limited Review Report of the Statutory Auditors thereon. 3. Press release on financial results. Appointment of Senior Management Personnel Approved appointment of Mr. B. Vara Prasad, General Manager (Engineering Purchase) and Mr. J. Srinivasa Rao, General Manager (Raw Materials Purchase) as Senior Management Personnel of the Company as recommended by the Nomination and Remuneration Committee, with effect from August 01, 2026. The details required under Regulation 30 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure – I. Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad -500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com Divi 's Laboratories Limited The Board meeting commenced at 10.15 Hrs and concluded at 11.20 Hrs. This is for your information and records. Thanking you, Yours faithfully, For Divi's Laboratories Limited M.Satish Choudhury Company Secretary & Compliance Officer Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad -500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026 (tin Crores s. Quarter ended Year ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 No. Particulars (Unaudited) (Audited)** (Unaudited) (Audited) 1 Income Revenue from operations 2974 2793 2357 10388 Other income 63 154 119 506 Total income 3037 2947 2476 10894 2 Exoenses a) Cost of materials consumed 1495 1173 989 4260 b) Purchases of stock-in-trade - - - - c) Changes in inventories of finished goods, work-in- (567) (70) (72) (244) progress, and stock-in-trade d) Employee benefits exoense 397 370 330 1400 e) Depreciation and amortization expense 132 120 112 461 f) Finance costs 6 6 3 23 g) Other expenses 409 377 367 1484 Total expenses 1872 1976 1729 7384 3 Profit before exceotional items and tax {1-2) 1165 971 747 3510 4 Exceptional items -Impact of New Labour codes - - - 74 5 Profit before tax (3-4) 1165 971 747 3436 6 Tax expense a) Current tax 290 250 191 869 b) Deferred tax (16) (35) (1) (40) Total tax expense 274 215 190 829 7 Profit for the period (5-6) 891 756 557 2607 8 Other comorehensive income: Items that will not be reclassified to Profit or Loss: (i) Gain/(Loss) on Remeasurement of 2 (8) (I) 8 post-employment benefit obligation (ii) Income tax relating to the above (I) 2 -* (2) Total other comprehensive income (i+ii) 1 (6) (I) 6 9 Total comprehensive income (7+8) 892 750 556 2613 10 Paid-up Equitv Share Capital 53 53 53 53 11 Other equity excluding revaluation reserve 16658 12 Earnings per Share# (Face Value Rs.2/-each) (not annualized) a) Basic (Rs.) 33.55 28.44 20.95 98.19 b) Diluted (Rs.) 33.55 28.44 20.95 98.19 # Eammgs per share calculated on actual amount of profit after tax in rupees *A mount is below the rounding off norms adopted by the company. Notes: 1. The above Statement of standalone unaudited financial results for the quarter ended 30th June, 2026 ("Standalone statement") is prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Standalone statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 01, 2026. The statutory auditors have carried out a limited review of the Standalone statement and issued an unmodified report thereon. 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. 3. The Company does not have any discontinued operations and the profit for the period represents profits from continuing operations only. 4. **Financial results for the quarter ended 31.03.2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year, which were subjected to limited review. 5. Details offorex gain/(loss) are as given below: (t in Crores) Quarter Ended Year Ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Price Waterhouse Chartered Accountants LLP Review Report The Board of Directors M/s Divi's Laboratories Limited Divi Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032 1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying "Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2026" (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review. 2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that mig [Showing first 8,000 characters — download PDF for full document]